Transparent Cap-assisted Endoscopic Sclerotherapy
Transparent Cap-assisted Endoscopic Sclerotherapy
The aim of this study is to evaluate efficacy and safety of transparent cap-assisted
 endoscopic sclerotherapyI(lauromacrogol injection) in management of esophageal varices.
Endoscopic procedures now play a great role in management of esophagogastric varices.
 Endoscopic variceal ligation(EVL) was recommended as first line therapy for primary and
 secondary prophylaxis in patients with esophageal varices. Previous studies have showed a
 superiority of EVL over endoscopic injection of sclerotherapy(EIS), mainly because of lower
 occurrence rate of complications. Procedure related complications were related to total
 amount of lauromacrogol, number of treatment and expertise of the endoscopists. Transparent
 cap has already been reported to assist in other endoscopic procedures, such as biopsy of
 Barret esophagus or endoscopic submucosal dissection. Accuracy and vision were improved with
 the help of transparent cap in the front of endoscopy. We have tried transparent cap-assisted
 sclerotherapy in some patients with in our hospital. Now a randomized controlled trial was
 conducted to evaluate efficacy and safety of transparent cap-assisted endoscopic
 sclerotherapy in management of esophageal varices.
Inclusion Criteria:

 -  Patients presented to our hospital with esophageal varices diagnosed by gastroscopy,
 with or without gastric varices.

 -  The age of the patients range from 18 to 80 years old.

 Exclusion Criteria:

 -  Patients who have contraindications for lauromacrogol therapy or transparent cap.

 -  Patients who have no previous upper gastrointestinal bleeding history.

 -  Patients who have fecal disease that could greatly impact survival, such as uremia,
 advanced cancer or respiratory failure, et al.